{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:49:42Z","timestamp":1783129782499,"version":"3.54.6"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Myelodysplastic neoplasms (MDS) are characterized by ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. One of the main treatment goals is improving quality of life (QoL), particularly for patients with lower-risk MDS (LR-MDS) who may live longer with compromised QoL. The QOL-E<jats:sup>\u00a9<\/jats:sup> is a patient-reported outcome (PRO) measure specifically developed to address the lack of a health-related QoL questionnaire for patients with MDS. The objective of this study was to evaluate the psychometric performance of the QOL-E in patients with LR-MDS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from four clinical trials in MDS (MEDALIST, DARB-MDS, EQoL-MDS, and RevMDS trials) were used to assess construct validity, reliability, and responsiveness. The QOL-E was validated by the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire \u2013 Core 30 (QLQ-C30) and clinical outcomes. It contains 29 items with the first two items assessing the patient\u2019s general well-being and the 27 remaining items grouped into six domain scores: physical well-being (QOL-FIS), functional well-being (QOL-FUN), social\/family well-being (QOL-SOC), sexual well-being (QOL-SEX), fatigue (QOL-FAT), and MDS-specific disturbances (QOL-MDSS). Additionally, meaningful within-patient change (MWPC) thresholds were determined for the domains and summary scores of the QOL-E using anchor-based analyses, supported by distribution-based analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 458 patients were included in the analyses. The QOL-E domain\/summary scores demonstrated acceptable convergent\/divergent and known-groups validity. Test-retest reliability and internal consistency was confirmed with intraclass correlation coefficients and Cronbach alpha exceeding 0.70 across most QOL-E domains\/summary scores. The QOL-E domains\/summary scores, except for QOL-SEX, had an adequate ability to detect change from baseline to Week 24. MWPC thresholds were proposed for all other domains and summary scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study results demonstrate that the QOL-E is generally fit for purpose to assess treatment effects in populations with LR-MDS and the proposed MWPC thresholds can be used to assess within-patient treatment effect on PROs, as assessed by the QOL-E, in future studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1507854","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T06:50:07Z","timestamp":1738911007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms"],"prefix":"10.3389","volume":"15","author":[{"given":"Esther Natalie","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shien","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lord-Bessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sanpaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Pelligra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-453068","article-title":"How we treat lower-risk myelodysplastic syndromes","volume":"121","author":"Fenaux","year":"2013","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13450","article-title":"Validation of the Revised International Prognostic Scoring System (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry","volume":"170","author":"de Swart","year":"2015","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0089-x","article-title":"Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study","volume":"32","author":"Stauder","year":"2018","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2010.02.003","article-title":"Hematopoietic stem cell transplantation for MDS","volume":"24","author":"Bartenstein","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.478","article-title":"Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens","volume":"2016","author":"Saber","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.453","article-title":"Current treatment algorithm for the management of lower-risk MDS","volume":"2017","author":"Giagounidis","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.07.003","article-title":"Current therapy of myelodysplastic syndromes","volume":"27","author":"Zeidan","year":"2013","journal-title":"Blood Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8494738","article-title":"Transfusion thresholds, quality of life, and current approaches in myelodysplastic syndromes","volume":"2016","author":"Koutsavlis","year":"2016","journal-title":"Anemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.664","article-title":"Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron","author":"Leitch","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21503","article-title":"Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review","volume":"84","author":"Pinchon","year":"2009","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstrom-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2006.06.004","article-title":"Strategies for achieving transfusion independence in myelodysplastic syndromes","volume":"11","author":"Thomas","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1188\/12.cjon.s1.47-57","article-title":"The importance of quality of life for patients living with myelodysplastic syndromes","volume":"16","author":"Thomas","year":"2012","journal-title":"Clin J Oncol Nurs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071610","article-title":"Risk-adapted, individualized treatment strategies of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)","volume":"13","author":"Bewersdorf","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2478\/s11536-013-0196-z","article-title":"Development and validation of Qol-E\u00a9 instrument for the assessment of health-related quality of life in myelodysplastic syndromes","volume":"8","author":"Oliva","year":"2013","journal-title":"Cent Eur J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010027","article-title":"Health-related quality of life outcomes in patients with myelodysplastic syndromes with ring sideroblasts treated with luspatercept in the MEDALIST phase 3 trial","volume":"11","author":"Oliva","year":"2022","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003728610","article-title":"Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life","volume":"51","author":"Oliva","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02699","article-title":"Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: interim results of a phase ii, randomized, placebo-controlled clinical trial (EQoL-MDS)","volume":"41","author":"Oliva","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.778406","article-title":"Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy","volume":"54","author":"Oliva","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B26","unstructured":"Patient-reported outcome measures: use in medical product development to support labeling claims\n          \n          \n          \n          2009"},{"key":"B27","unstructured":"Patient-focused drug development guidance: methods to identify what is important to patients & Select, develop or modify fit-for-purpose clinical outcomes assessments\n          \n          \n          \n          2018"},{"key":"B28","unstructured":"Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making\n          \n          \n          \n          2023"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002525","article-title":"What determines patient satisfaction with surgery? A prospective cohort study of 4709 Patients following total joint replacement","volume":"3","author":"Hamilton","year":"2013","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007765","article-title":"Floor and ceiling effects in the OHS: an analysis of the NHS proms data set","volume":"5","author":"Lim","year":"2015","journal-title":"BMJ Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Quality criteria were proposed for measurement properties of health status questionnaires","volume":"60","author":"Terwee","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"B32","volume-title":"Patient-reported outcomes: measurement, implementation and interpretation","author":"Cappelleri","year":"2014"},{"key":"B33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","article-title":"Forming inferences about some intraclass correlation coefficients","volume":"1","author":"McGraw","year":"1996","journal-title":"Psychol Methods"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-2076-0","article-title":"Assessing test-retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula","volume":"28","author":"Qin","year":"2019","journal-title":"Qual Life Res"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-0753-5_1494","article-title":"Internal consistency reliability","volume-title":"Encyclopedia of quality of life and well-being research","author":"Revicki","year":"2014"},{"key":"B36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02310555","article-title":"Coefficient alpha and the internal structure of tests","volume":"16","author":"Cronbach","year":"1951","journal-title":"Psychometrika"},{"key":"B37","first-page":"56","article-title":"The alpha and the omega of scale reliability and validity: why and how to abandon Cronbach\u2019s alpha and the route towards more comprehensive assessment of scale quality","volume":"16","author":"Peters","year":"2014","journal-title":"Eur Health Psychol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/0013164416658325","article-title":"Testing the difference between reliability coefficients alpha and omega","volume":"77","author":"Deng","year":"2017","journal-title":"Educ Psychol Meas"},{"key":"B39","first-page":"485","volume-title":"Test theory: A unified treatment","author":"McDonald","year":"1999"},{"key":"B40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/a:1015291021312","article-title":"Assessing health status and quality-of-life instruments: attributes and review criteria","volume":"11","author":"Lohr","year":"2002","journal-title":"Qual Life Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1081\/BIP-120028508","article-title":"Minimal important difference thresholds and the standard error of measurement: is there a connection","volume":"14","author":"Wyrwich","year":"2004","journal-title":"J Biopharm Stat"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132541","article-title":"Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa","volume":"22","author":"Lefebvre","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185865","article-title":"MDS-related anemia is associated with impaired quality of life but improvement is not always achieved by increased hemoglobin level","volume":"12","author":"Haring","year":"2023","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2004.0040","article-title":"Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa","volume":"2","author":"Shasha","year":"2004","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507854\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T06:50:14Z","timestamp":1738911014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507854\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":46,"alternative-id":["10.3389\/fonc.2025.1507854"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1507854","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"article-number":"1507854"}}